Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| uniQure N.V.QURE · Entity 4162 | Director · CEO, Managing Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
uniQure N.V.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 519,227 |
Ending reported balance
After 2026-07-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-02 · Exercise / conversion · Acquired 21,082 · Balance 540,309 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Row 2 · 2026-07-02 · Sale · Disposed 9,200 · Balance 531,109 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.10 to $44.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-07-02 · Sale · Disposed 4,282 · Balance 526,827 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-07-02 · Sale · Disposed 7,600 · Balance 519,227 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.48 to $46.10. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.39 · Expires 2028-01-26 | Direct | 0 |
Reported balance
After 2026-07-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-02 · Exercise / conversion · Disposed 21,082 · Balance 0 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5: The Stock Option vested in full on January 26, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.10 to $44.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.48 to $46.10. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The Stock Option vested in full on January 26, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Decibel Therapeutics, Inc.
Report date September 25, 2023 · Filed September 25, 2023
Section 16 reporting ended · disclosed 2023-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 1
1 source rowRow 1 · 2023-09-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3: Includes 10,000 unvested Company RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2033-03-18 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"),
F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU.
F3: Includes 10,000 unvested Company RSUs.
F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2024 Filed Feb 28, 2024 21:17 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 27,904 | $6.35 | $177,190.40 |
DisclosureSEC source: 0000904454-24-000187 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,839 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.23 to $6.49. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 20:24 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $3.34 | Not disclosed |
DisclosureSEC source: 0000899243-23-019489 · doc4.xml · derivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-03-18 F4 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 20:24 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019489 · doc4.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2 · shares: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3 · shares: Includes 10,000 unvested Company RSUs. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2 · price: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. Read SEC document |
| March 19, 2023 Filed Mar 21, 2023 20:13 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Options (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0000899243-23-009282 · doc4.xml · derivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-03-18 F3 · derivative.exercise_date: The option was granted on March 19, 2023. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service. Read SEC document |
| March 19, 2023 Filed Mar 21, 2023 20:13 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009282 · doc4.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Consists of shares of the Issuer's common stock issuable under 10,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest in equal annual installments until the third anniversary of the grant date, subject to the reporting person's continued service. F2 · balance_after: Includes 10,000 unvested RSUs. Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:58 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,521 | $21.39 | $53,924.19 |
DisclosureSEC source: 0000904454-23-000215 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,743 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of performance-based restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.35 to $21.42. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 21:13 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 5,021 | $20.90 | $104,938.90 |
DisclosureSEC source: 0000899243-23-006579 · doc4.xml · nonDerivative · entry 3 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,264 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.79 to $21.39. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:13 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,385 | $20.24 | $28,032.40 |
DisclosureSEC source: 0000899243-23-006579 · doc4.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,285 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.20 to $20.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:13 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 18,141 | $19.86 | $360,280.26 |
DisclosureSEC source: 0000899243-23-006579 · doc4.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,670 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.20 to $20.17. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:05 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 256,500 | $0.00 Strike: $20.06 | $0.00 |
DisclosureSEC source: 0000904454-23-000184 · edgar.xml · derivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,500 Underlying: Ordinary Shares · 256,500 shares Expires 2033-02-23 F2 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:05 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 121,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-23-000184 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,811 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 21:04 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 5,830 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005830 · doc4.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,311 F1 · shares: Represents performance-based restricted share units ("PRSUs") granted to the Reporting Person on December 8, 2021 under the Issuer's 2014 Share Incentive Plan, as amended and restated, which were earned on February 20, 2023 as the result of the satisfaction of certain performance criteria. Each PRSU represents the contingent right to receive one Ordinary Share. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 20:34 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 6,648 | $22.44 | $149,181.12 |
DisclosureSEC source: 0000904454-22-000611 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,481 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of performance-based restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.39 to $22.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 21:00 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 14,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037025 · doc4.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,129 F1 · shares: Represents performance-based restricted share units ("PRSUs") granted to the Reporting Person on December 8, 2021 under the Issuer's 2014 Share Incentive Plan, as amended and restated, which vested on November 22, 2022 as the result of the satisfaction of certain performance criteria. Each PRSU represents the contingent right to receive one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:01 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 10,195 | $16.70 | $170,256.50 |
DisclosureSEC source: 0000904454-22-000209 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO & Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,554 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.60 to $16.86. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:09 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 215,643 | $0.00 Strike: $16.04 | $0.00 |
DisclosureSEC source: 0000904454-22-000177 · edgar.xml · derivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO and Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,643 Underlying: Ordinary Shares · 215,643 shares Expires 2032-02-24 F2 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:09 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 125,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000177 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO and Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,749 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:56 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 10,901 | $18.10 | $197,308.10 |
DisclosureSEC source: 0000904454-22-000067 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,676 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.93 to $18.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:14 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 117 | $28.64 | $3,350.88 |
DisclosureSEC source: 0000904454-21-000632 · edgar.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,577 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.52 to $28.79. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:14 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 883 | $28.08 | $24,794.64 |
DisclosureSEC source: 0000904454-21-000632 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,694 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.52 to $28.51. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 14, 2021 Filed Jul 21, 2021 18:00 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,000 | $27.77 | $27,770.00 |
DisclosureSEC source: 0000904454-21-000595 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,577 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.47 to $28.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 14:33 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,900 | $35.00 | $66,500.00 |
DisclosureSEC source: 0000904454-21-000549 · edgar.xml · nonDerivative · entry 3 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,577 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.01. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 14:33 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,993 | $34.89 | $69,535.77 |
DisclosureSEC source: 0000904454-21-000549 · edgar.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,477 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.51 to $35.08. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 14:33 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,457 | $34.26 | $49,916.82 |
DisclosureSEC source: 0000904454-21-000549 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,470 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.51 to $34.501. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2021 Filed May 14, 2021 15:46 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,250 | $32.29 | $72,652.50 |
DisclosureSEC source: 0000904454-21-000451 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,927 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.14 to $32.61. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 14, 2021 Filed Apr 22, 2021 13:28 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,718 | $35.59 | $61,143.62 |
DisclosureSEC source: 0000904454-21-000415 · edgar.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,177 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.48 to $35.96. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 14, 2021 Filed Apr 22, 2021 13:28 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 3,632 | $35.07 | $127,374.24 |
DisclosureSEC source: 0000904454-21-000415 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,895 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.47 to $35.44. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 22, 2021 17:11 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 6 | $34.54 | $207.24 |
DisclosureSEC source: 0000904454-21-000361 · edgar.xml · nonDerivative · entry 3 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,527 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.51 to $34.55. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 22, 2021 17:11 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 456 | $33.98 | $15,494.88 |
DisclosureSEC source: 0000904454-21-000361 · edgar.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,533 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.50 to $34.49. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 22, 2021 17:11 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,788 | $32.95 | $58,914.60 |
DisclosureSEC source: 0000904454-21-000361 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,989 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.50 to $33.49. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 18:39 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 4,974 | $36.94 | $183,739.56 |
DisclosureSEC source: 0000904454-21-000280 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,777 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.40 to $36.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:23 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 96,229 | $0.00 Strike: $37.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000246 · edgar.xml · derivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,229 Underlying: Ordinary Shares · 96,229 shares Expires 2031-02-25 F2 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:23 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 55,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000246 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,751 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| February 15, 2021 Filed Feb 24, 2021 17:46 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,750 | $35.97 | $62,947.50 |
DisclosureSEC source: 0000904454-21-000241 · edgar.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,938 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.51 to $36.27. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2021 Filed Feb 24, 2021 17:46 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,050 | $34.88 | $71,504.00 |
DisclosureSEC source: 0000904454-21-000241 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,688 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.43 to $35.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:04 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 884 | $36.19 | $31,991.96 |
DisclosureSEC source: 0000904454-21-000098 · edgar.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,738 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.00 to $36.53. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:04 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 6,116 | $35.49 | $217,056.84 |
DisclosureSEC source: 0000904454-21-000098 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,622 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.96 to $35.93. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 18:53 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,701 | $36.86 | $62,698.86 |
DisclosureSEC source: 0000904454-21-000096 · edgar.xml · nonDerivative · entry 5 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,738 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.60 to $37.47. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 18:53 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 14,049 | $35.96 | $505,202.04 |
DisclosureSEC source: 0000904454-21-000096 · edgar.xml · nonDerivative · entry 4 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,439 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.60 to $36.59. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 18:48 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,701 | $36.86 | $62,698.86 |
DisclosureSEC source: 0000904454-21-000094 · edgar.xml · nonDerivative · entry 5 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,738 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.60 to $37.47. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 18:48 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 14,049 | $35.96 | $505,202.04 |
DisclosureSEC source: 0000904454-21-000094 · edgar.xml · nonDerivative · entry 4 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,439 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.60 to $36.59. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 18:53 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 300 | $38.18 | $11,454.00 |
DisclosureSEC source: 0000904454-21-000096 · edgar.xml · nonDerivative · entry 3 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,488 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.14 to $38.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 18:53 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 9,339 | $37.57 | $350,866.23 |
DisclosureSEC source: 0000904454-21-000096 · edgar.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,788 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.14 to $38.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 18:53 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 6,110 | $36.59 | $223,564.90 |
DisclosureSEC source: 0000904454-21-000096 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,127 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.12 to $37.10. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 18:48 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 300 | $38.18 | $11,454.00 |
DisclosureSEC source: 0000904454-21-000094 · edgar.xml · nonDerivative · entry 3 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,488 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.14 to $38.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 18:48 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 9,339 | $37.57 | $350,866.23 |
DisclosureSEC source: 0000904454-21-000094 · edgar.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,788 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.14 to $38.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 18:48 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 6,110 | $36.59 | $223,564.90 |
DisclosureSEC source: 0000904454-21-000094 · edgar.xml · nonDerivative · entry 1 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,127 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units and performance-based restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.12 to $37.10. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2020 Filed Dec 21, 2020 13:12 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,501 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0000904454-20-000824 · edgar.xml · derivative · entry 4 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,817 Underlying: Ordinary Shares · 12,501 shares Expires 2026-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Stock Option vested 25% on September 29, 2017 (the first anniversary of the date of grant), and vests 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| December 16, 2020 Filed Dec 21, 2020 13:12 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,786 | $48.83 | $87,210.38 |
DisclosureSEC source: 0000904454-20-000824 · edgar.xml · nonDerivative · entry 3 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,237 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.71 to $48.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2020 Filed Dec 21, 2020 13:12 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 10,715 | $48.34 | $517,963.10 |
DisclosureSEC source: 0000904454-20-000824 · edgar.xml · nonDerivative · entry 2 Kapusta Matthew C · CIK 0001536290 · Director · CEO, CFO, Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,023 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.71 to $48.69. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.